BidaskClub Downgrades Geron (GERN) to Sell

Geron (NASDAQ:GERN) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Wednesday.

GERN has been the topic of a number of other reports. ValuEngine downgraded Geron from a “buy” rating to a “hold” rating in a research report on Friday, May 11th. Zacks Investment Research raised Geron from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Tuesday, April 24th. Stifel Nicolaus lifted their target price on Geron from $2.50 to $4.00 and gave the stock a “hold” rating in a research report on Sunday, March 18th. Finally, Piper Jaffray reissued a “buy” rating and set a $7.00 target price on shares of Geron in a research report on Monday, March 19th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $5.17.

GERN stock opened at $3.38 on Wednesday. Geron has a twelve month low of $3.31 and a twelve month high of $3.44.

Geron (NASDAQ:GERN) last released its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. Geron had a negative return on equity of 26.20% and a negative net margin of 3,300.12%. The business had revenue of $0.32 million for the quarter. During the same period last year, the business earned ($0.05) earnings per share. research analysts anticipate that Geron will post 0.19 earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. DekaBank Deutsche Girozentrale acquired a new stake in Geron during the first quarter valued at approximately $106,000. MetLife Investment Advisors LLC acquired a new stake in Geron during the fourth quarter valued at approximately $136,000. Millennium Management LLC boosted its holdings in Geron by 573.5% during the fourth quarter. Millennium Management LLC now owns 101,800 shares of the biopharmaceutical company’s stock valued at $183,000 after purchasing an additional 86,684 shares in the last quarter. Element Capital Management LLC acquired a new stake in Geron during the first quarter valued at approximately $227,000. Finally, Bayesian Capital Management LP acquired a new stake in Geron during the first quarter valued at approximately $250,000. 36.67% of the stock is currently owned by institutional investors.

About Geron

Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply